The CD4+ T-cell epitope-binding register is a critical parameter when generating functional HLA-DR tetramers with promiscuous peptides

European Journal of Immunology

Volumn 40, Issue 6, 2010, Pages 1603-1616

  Cecconi, Virginia ^a   Moro, Monica ^a,d   Del Mare, Sara ^a,e   Sidney, John ^b   Bachi, Angela ^a   Longhi, Renato ^c   Sette, Alessandro ^b   Protti, Maria Pia ^a   Dellabona, Paolo ^a   Casorati, Giulia ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^c CNR   (Italy)

^d Istituto Nazionale di Genetica Molecolare   (Italy)

^e HEBREW UNIVERSITY   (Israel)

Author keywords

Anchor residues; HLA DR*1101; MAGE A3; MHC tetramers; Tumor antigens

Indexed keywords

EPITOPE; HLA DR ANTIGEN; HLA DR ANTIGEN 1101; MELANOMA ANTIGEN 3; MELANOMA ANTIGEN 3 [191-205]; MELANOMA ANTIGEN 3 [277-306]; MELANOMA ANTIGEN 3 [281-295]; MELANOMA ANTIGEN 3 [286-300]; MELANOMA ANTIGEN 3 [287-298]; MELANOMA ANTIGEN 3 [288-302]; MONOMER; PEPTIDE; TETRAMER; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; BIOINFORMATICS; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOLECULAR RECOGNITION; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN BINDING; T LYMPHOCYTE ACTIVATION;

ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CELL SEPARATION; EPITOPES, T-LYMPHOCYTE; FLOW CYTOMETRY; HLA-DR ANTIGENS; HUMANS; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; POLYMERASE CHAIN REACTION;

EID: 77953306821     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.200940123     Document Type: Article

References (57)

1. Pardoll, D. M. and Topalian, S. L., The role of CD4+ T cell responses in antitumor immunity. Curr. Opin. Immunol. 1998. 10: 588-594.
2. Knutson, K. L. and Disis, M. L., Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol. Immunother. 2005. 54: 721-728.
3. Bioley, G., Jandus, C., Tuyaerts, S., Rimoldi, D., Kwok,W.W., Speiser, D. E., Tiercy, J. M. et al., Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers. J. Immunol. 2006. 177: 6769-6779.
4. Zhang, Y., Renkvist, N., Sun, Z., Schuler-Thurner, B., Glaichenhaus, N., Schuler, G., Boon, T. et al., A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells. Eur. J. Immunol. 2005. 35: 1066-1075.
5. Zhang, Y., Sun, Z., Nicolay, H., Meyer, R. G., Renkvist, N., Stroobant, V., Corthals, J. et al., Monitoring of anti-vaccine CD4 T cell frequencies in melanoma patients vaccinated with a MAGE-3 protein. J. Immunol. 2005. 174: 2404-2411. (Pubitemid 40223990)
6. Francois, V., Ottaviani, S., Renkvist, N., Stockis, J., Schuler, G., Thielemans, K., Colau, D. et al., The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells. Cancer Res. 2009. 69: 4335-4345.
7. Vollers, S. S. and Stern, L. J., Class II major histocompatibility complex tetramer staining: progress, problems, and prospects. Immunology 2008. 123: 305-313. (Pubitemid 351171199)
8. Cecconi, V., Moro, M., Del Mare, S., Dellabona, P. and Casorati, G., Use of MHC class II tetramers to investigate CD41 T cell responses: problems and solutions. Cytometry A 2008. 73: 1010-1018.
9. Crawford, F., Kozono, H., White, J., Marrack, P. and Kappler, J., Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes. Immunity 1998. 8: 675-682. (Pubitemid 28294514)
10. Reichstetter, S., Ettinger, R. A., Liu, A. W., Gebe, J. A., Nepom, G. T. and Kwok, W. W., Distinct T cell interactions with HLA class II tetramers characterize a spectrum of TCR affinities in the human antigen-specific T cell response. J. Immunol. 2000. 165: 6994-6998. (Pubitemid 32001171)
11. Gebe, J. A., Falk, B. A., Rock, K. A., Kochik, S. A., Heninger, A. K., Reijonen, H., Kwok, W. W. and Nepom, G. T., Low-avidity recognition by CD4+ T cells directed to self-antigens. Eur. J. Immunol. 2003. 33: 1409-1417.
12. Moro, M., Cecconi, V., Martinoli, C., Dallegno, E., Giabbai, B., Degano, M., Glaichenhaus, N. et al., Generation of functional HLA-DR*1101 tetramers receptive for loading with pathogen- or tumour-derived synthetic peptides. BMC Immunol. 2005. 6: 24. (Pubitemid 41800237)
13. Falta, M. T., Fontenot, A. P., Rosloniec, E. F., Crawford, F., Roark, C. L., Bill, J., Marrack, P. et al., Class II major histocompatibility complex-peptide tetramer staining in relation to functional avidity and T cell receptor diversity in the mouse CD4(+) T cell response to a rheumatoid arthritis-associated antigen. Arthritis Rheum. 2005. 52: 1885-1896.
14. Novak, E. J., Masewicz, S. A., Liu, A. W., Lernmark, A., Kwok, W. W. and Nepom, G. T., Activated human epitope-specific T cells identified by class II tetramers reside within a CD4high, proliferating subset. Int. Immunol. 2001. 13: 799-806.
15. Cameron, T. O., Cochran, J. R., Yassine-Diab, B., Sekaly, R. P. and Stern, L. J., Cutting edge: detection of antigen-specific CD4+ T cells by HLA-DR1 oligomers is dependent on the T cell activation state. J. Immunol. 2001. 166: 741-745.
16. Brown, J. H., Jardetzky, T. S., Gorga, J. C., Stern, L. J., Urban, R. G., Strominger, J. L. and Wiley, D. C., Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993. 364: 33-39.
17. Stern, L. J., Brown, J. H., Jardetzky, T. S., Gorga, J. C., Urban, R. G., Strominger, J. L. and Wiley, D. C., Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994. 368: 215-221.
18. Fremont, D. H., Hendrickson, W. A., Marrack, P. and Kappler, J., Structures of an MHC class II molecule with covalently bound single peptides. Science 1996. 272: 1001-1004.
19. Viner, N. J., Nelson, C. A., Deck, B. and Unanue, E. R., Complexes generated by the binding of free peptides to class II MHC molecules are antigenically diverse compared with those generated by intracellular processing. J. Immunol. 1996. 156: 2365-2368. (Pubitemid 26091558)
20. McFarland, B. J., Sant, A. J., Lybrand, T. P. and Beeson, C., Ovalbumin(323-339) peptide binds to the major histocompatibility complex class II I-A(d) protein using two functionally distinct registers. Biochemistry 1999. 38: 16663-16670.
21. Lonchay, C., van der Bruggen, P., Connerotte, T., Hanagiri, T., Coulie, P., Colau, D., Lucas, S. et al., Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc. Natl. Acad. Sci. USA 2004. 101: 14631-14638.
22. Bankovich, A. J., Girvin, A. T., Moesta, A. K. and Garcia, K. C., Peptide register shifting within the MHC groove: theory becomes reality. Mol. Immunol. 2004. 40: 1033-1039.
23. Gaugler, B., Van den Eynde, B., van der Bruggen, P., Romero, P., Gaforio, J. J., De Plaen, E., Lethe, B. et al., Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. 1994. 179: 921-930.
24. Van Der Bruggen, P., Zhang, Y., Chaux, P., Stroobant, V., Panichelli, C., Schultz, E. S., Chapiro, J. et al., Tumor-specific shared antigenic peptides recognized by human T cells. Immunol. Rev. 2002. 188: 51-64.
25. Kruit, W. H., van Ojik, H. H., Brichard, V. G., Escudier, B., Dorval, T., Dreno, B., Patel, P. et al., Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int. J. Cancer 2005. 117: 596-604.
26. Thurner, B., Haendle, I., Roder, C., Dieckmann, D., Keikavoussi, P., Jonuleit, H., Bender, A. et al., Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 1999. 190: 1669-1678.
27. Marchand, M., Punt, C. J., Aamdal, S., Escudier, B., Kruit, W. H., Keilholz, U., Hakansson, L. et al., Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur. J. Cancer 2003. 39: 70-77. (Pubitemid 36005427)
28. Brichard, V. G. and Lejeune, D., GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development. Vaccine 2007. 25: B61-B71. (Pubitemid 47488551)
29. Atanackovic, D., Altorki, N. K., Cao, Y., Ritter, E., Ferrara, C. A., Ritter, G., Hoffman, E. W., Bokemeyer, C., Old, L. J. and Gnjatic, S., Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc. Natl. Acad. Sci. USA 2008. 105: 1650-1655.
30. Manici, S., Sturniolo, T., Imro, M. A., Hammer, J., Sinigaglia, F., Noppen, C., Spagnoli, G. et al., Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J. Exp. Med. 1999. 189: 871-876.
31. Consogno, G., Manici, S., Facchinetti, V., Bachi, A., Hammer, J., Conti- Fine, B. M., Rugarli, C. et al., Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3. Blood 2003. 101: 1038-1044. (Pubitemid 36139377)
32. Sturniolo, T., Bono, E., Ding, J., Raddrizzani, L., Tuereci, O., Sahin, U., Braxenthaler, M. et al., Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat. Biotechnol. 1999. 17: 555-561.
33. Marturano, J., Longhi, R., Russo, V. and Protti, M. P., Endosomal proteases influence the repertoire of MAGE-A3 epitopes recognized in vivo by CD4+ T cells. Cancer Res. 2008. 68: 1555-1562. (Pubitemid 351346865)
34. Chaux, P., Vantomme, V., Stroobant, V., Thielemans, K., Corthals, J., Luiten, R., Eggermont, A. M. et al., Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(1) T lymphocytes. J. Exp. Med. 1999. 189: 767-778.
35. Singh, H. and Raghava, G. P., ProPred: prediction of HLA-DR binding sites. Bioinformatics 2001. 17: 1236-1237. (Pubitemid 33735355)
36. Carson, R. T., Vignali, K. M., Woodland, D. L. and Vignali, D. A., T cell receptor recognition of MHC class II-bound peptide flanking residues enhances immunogenicity and results in altered TCR V region usage. Immunity 1997. 7: 387-399.
37. He, X. L., Radu, C., Sidney, J., Sette, A., Ward, E. S. and Garcia, K. C., Structural snapshot of aberrant antigen presentation linked to autoimmunity: the immunodominant epitope of MBP complexed with I-Au. Immunity 2002. 17: 83-94.
38. Nelson, C. A., Petzold, S. J. and Unanue, E. R., Identification of two distinct properties of class II major histocompatibility complex-associated peptides. Proc. Natl. Acad. Sci. USA 1993. 90: 1227-1231.
39. Sant'Angelo, D. B., Robinson, E., Janeway Jr, C. A. and Denzin, L. K., Recognition of core and flanking amino acids of MHC class II-bound peptides by the T cell receptor. Eur. J. Immunol. 2002. 32: 2510-2520.
40. Latek, R. R. and Unanue, E. R., Mechanisms and consequences of peptide selection by the I-Ak class II molecule. Immunol. Rev. 1999. 172: 209-228.
41. Wack, A., Montagna, D., Dellabona, P. and Casorati, G., An improved PCR-heteroduplex method permits high-sensitivity detection of clonal expansions in complex T cell populations. J. Immunol. Methods 1996. 196: 181-192. (Pubitemid 26306739)
42. Cunliffe, S. L., Wyer, J. R., Sutton, J. K., Lucas, M., Harcourt, G., Klenerman, P., McMichael, A. J. and Kelleher, A. D., Optimization of peptide linker length in production of MHC class II/peptide tetrameric complexes increases yield and stability, and allows identification of antigen-specific CD4+ T cells in peripheral blood mononuclear cells. Eur. J. Immunol. 2002. 32: 3366-3375.
43. Demotte, N., Stroobant, V., Courtoy, P. J., Van Der Smissen, P., Colau, D., Luescher, I. F., Hivroz, C. et al., Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes. Immunity 2008. 28: 414-424.
44. James, E. A., Bui, J., Berger, D., Huston, L., Roti, M. and Kwok, W. W., Tetramer-guided epitope mapping reveals broad, individualized repertoires of tetanus toxin-specific CD41 T cells and suggests HLA-based differences in epitope recognition. Int. Immunol. 2007. 19: 1291-1301.
45. Nanda, N. K., Arzoo, K. K., Geysen, H. M., Sette, A. and Sercarz, E. E., Recognition of multiple peptide cores by a single T cell receptor. J Exp Med. 1995. 182: 531-539.
46. Diepolder, H. M., Gerlach, J. T., Zachoval, R., Hoffmann, R. M., Jung, M. C., Wierenga, E. A., Scholz, S. et al., Immunodominant CD41 T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J. Virol. 1997. 71: 6011-6019.
47. O'Sullivan, D., Sidney, J., Del Guercio, M. F., Colon, S. M. and Sette, A., Truncation analysis of several DR binding epitopes. J. Immunol. 1991. 146: 1240-1246.
48. O'Sullivan, D., Arrhenius, T., Sidney, J., Del Guercio, M. F., Albertson, M., Wall, M., Oseroff, C. et al., On the interaction of promiscuous antigenic peptides with different DR alleles. Identification of common structural motifs. J. Immunol. 1991. 147: 2663-2669.
49. Landais, E., Romagnoli, P. A., Corper, A. L., Shires, J., Altman, J. D., Wilson, I. A., Garcia, K. C. and Teyton, L., New design of MHC class II tetramers to accommodate fundamental principles of antigen presentation. J. Immunol. 2009. 183: 7949-7957.
50. Gilboa, E., The makings of a tumor rejection antigen. Immunity 1999. 11: 263-270.
51. Parmiani, G., De Filippo, A., Novellino, L. and Castelli, C., Unique human tumor antigens: immunobiology and use in clinical trials. J. Immunol. 2007. 178: 1975-1979.
52. Vignali, D. A. and Strominger, J. L., Amino acid residues that flank core peptide epitopes and the extracellular domains of CD4 modulate differential signaling through the T cell receptor. J. Exp. Med. 1994. 179: 1945-1956.
53. Dellabona, P., Casorati, G., Friedli, B., Angman, L., Sallusto, F., Tunnacliffe, A., Roosneek, E. and Lanzavecchia, A., In vivo persistence of expanded clones specific for bacterial antigens within the human T cell receptor alpha/beta CD4-8-subset. J. Exp. Med. 1993. 177: 1763-1771.
54. Guillaume, P., Legler, D. F., Boucheron, N., Doucey, M. A., Cerottini, J. C. and Luescher, I. F., Soluble major histocompatibility complex-peptide octamers with impaired CD8 binding selectively induce Fas-dependent apoptosis. J. Biol. Chem. 2003. 278: 4500-4509.
55. Curnis, F., Gasparri, A., Sacchi, A., Longhi, R. and Corti, A., Coupling tumor necrosis factor-alpha with alphaV integrin ligands improves its antineoplastic activity. Cancer Res. 2004. 64: 565-571.
56. Sidney, J., Southwood, S., Oseroff, C., del Guercio, M. F., Sette, A. and Grey, H. M., Measurement of MHC/peptide interactions by gel filtration. Curr. Protoc. Immunol. 2001. Chapter 18: Unit 18.13.
57. Southwood, S., Sidney, J., Kondo, A., del Guercio, M. F., Appella, E., Hoffman, S., Kubo, R. T. et al., Several common HLA-DR types share largely overlapping peptide binding repertoires. J. Immunol. 1998. 160: 3363-3373.